|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosenberg JE, Carroll PR and Small EJ:
Update on chemotherapy for advanced bladder cancer. J Urol.
174:14–20. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein JP, Lieskovsky G, Cote R, Groshen S,
Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M,
et al: Radical cystectomy in the treatment of invasive bladder
cancer: Long-term results in 1,054 patients. J Clin Oncol.
19:666–675. 2001.PubMed/NCBI
|
|
4
|
Galsky MD, Moshier E, Krege S, Lin CC,
Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK and Bamias A: Nomogram
for predicting survival in patients with unresectable and/or
metastatic urothelial cancer who are treated with cisplatin-based
chemotherapy. Cancer. 119:3012–3019. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N,
et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for
advanced transitional cell carcinoma of the urothelium. Efficacy
and patterns of response and relapse. Cancer. 64:2448–2458. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multi-center, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI
|
|
7
|
Hussain M, Vaishampayan U, Du W, Redman B
and Smith DC: Combination paclitaxel, carboplatin, and gemcitabine
is an active treatment for advanced urothelial cancer. J Clin
Oncol. 19:2527–2533. 2001.PubMed/NCBI
|
|
8
|
Choi W, Porten S, Kim S, Willis D, Plimack
ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al:
Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to
frontline chemotherapy. Cancer Cell. 25:152–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nilsson S, Mäkelä S, Treuter E, Tujague M,
Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M and
Gustafsson JA: Mechanisms of estrogen action. Physiol Rev.
81:1535–1565. 2001.PubMed/NCBI
|
|
10
|
Harris HA: Estrogen receptor-beta: Recent
lessons from in vivo studies. Mol Endocrinol. 21:1–13. 2007.
View Article : Google Scholar
|
|
11
|
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu
I, Izumi K, Chang C, Messing EM, Netto GJ and Yeh S: Expression of
androgen and oestrogen receptors and its prognostic significance in
urothelial neoplasm of the urinary bladder. BJU Int. 109:1716–1726.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY,
Jian W, Sonpavde G, Ayala GE, Younes M and Lerner SP: Expression of
estrogen receptors-alpha and -beta in bladder cancer cell lines and
human bladder tumor tissue. Cancer. 106:2610–2616. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tuygun C, Kankaya D, Imamoglu A, Sertcelik
A, Zengin K, Oktay M and Sertcelik N: Sex-specific hormone
receptors in urothelial carcinomas of the human urinary bladder: A
comparative analysis of clinicopathological features and survival
outcomes according to receptor expression. Urol Oncol. 29:43–51.
2011. View Article : Google Scholar
|
|
14
|
Pfister C: New trends for optimal
management of bladder tumors. J Urol. 165:65–66. 2001. View Article : Google Scholar
|
|
15
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng A, Kallio A and Härkönen P:
Tamoxifen-induced rapid death of MCF-7 breast cancer cells is
mediated via extracellularly signal-regulated kinase signaling and
can be abrogated by estrogen. Endocrinology. 148:2764–2777. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jinesh GG, Choi W, Shah JB, Lee EK, Willis
DL and Kamat AM: Blebbishields, the emergency program for cancer
stem cells: Sphere formation and tumorigenesis after apoptosis.
Cell Death Differ. 20:382–395. 2013. View Article : Google Scholar :
|
|
18
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang P, Chubb S, Hertel LW, Grindey GB
and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA
synthesis. Cancer Res. 51:6110–6117. 1991.PubMed/NCBI
|
|
20
|
Brauch H and Jordan VC: Targeting of
tamoxifen to enhance anti-tumour action for the treatment and
prevention of breast cancer: The 'personalised' approach? Eur J
Cancer. 45:2274–2283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marshall E: Tamoxifen. 'A big deal,' but a
complex hand to play. Science. 280:1961998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Silvestris N, Cinieri S, La Torre I,
Pezzella G, Numico G, Orlando L and Lorusso V: Role of gemcitabine
in metastatic breast cancer patients: A short review. Breast.
17:220–226. 2008. View Article : Google Scholar
|
|
23
|
Cosco D, Paolino D, Cilurzo F, Casale F
and Fresta M: Gemcitabine and tamoxifen-loaded liposomes as
multidrug carriers for the treatment of breast cancer diseases. Int
J Pharm. 422:229–237. 2012. View Article : Google Scholar
|
|
24
|
Han B, Cui D, Jing Y, Hong Y and Xia S:
Estrogen receptor β (ERβ) is a novel prognostic marker of
recurrence survival in non-muscle-invasive bladder cancer
potentially by inhibiting cadherin switch. World J Urol.
30:861–867. 2012. View Article : Google Scholar : PubMed/NCBI
|
